Establishing a Foslevodopa–Foscarbidopa Service within a geriatric medicine Parkinson’s service

4761
T Jones 1; C Andrew 1; C Spencer 1; M Bonello 2
1. Mersey and West Lancashire Teaching Hospital NHS Trust 2. The Walton Centre NHS Foundation Trust
Clinical Quality
CQ - Improved Access to Service
Movement disorders

Abstract

Introduction

Our movement disorder service provides care for people living with Parkinson’s across 4 boroughs and 2 acute hospitals. There are predicted to be 1,671 people living with Parkinson’s in our area1.

Foslevodopa-foscarbidopa is indicated for the treatment of advanced levodopa-responsive Parkinson’s with severe motor fluctuations when available combinations of medications have not given satisfactory results and apomorphine or deep brain stimulation (DBS) are no longer effective or not appropriate2.

Method

Our service aims to proactively identify patients who are living with advance phase Parkinson’s using the Delphi Consensus 5:2:1 definition3. Advanced therapies are discussed with patients; if they wish to consider these patients are listed for discussion in our trust movement disorder MDT. The MDT consists of PD nurses specialists, geriatricians, physiotherapist, occupational therapists and pharmacists. If the MDT agrees the patients are then referred to the Cheshire, Merseyside and North Wales Neuroscience Network regional infusion MDT. The MDT is structured as a spoke and hub model. Approved patients have pre initiation assessments including MOCA, PDQ39 and videos. Patients attend as a day case for initiation and followed up. The pre initiation assessments are repeated 2 months post initiation.

Results

Currently we are the only spoke centre in Cheshire and Merseyside with an established service. Since July 2025, we have referred 10 patients to the regional MDT. 6 patients have been approved for Foslevodopa–Foscarbidopa. 3 are established on treatment, 2 are due to commence and 1 died prior to initiation. 2 patients have been referred for DBS. We will be able to present the MOCA / PDQ39 results at the conference and also discuss our experience of establishing the service.

Conclusion

Our service is improving access to advanced therapies for our patients. We will be able to share our patients experience of Foslevodopa–Foscarbidopa and their outcome measures.

Word Count: 299

References:

  1. https://parkinsonsuk.hsj.co.uk/estimated-number-people-parkinsons
  2. Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms. Technology appraisal guidance Reference number:TA934 Published: 29 November 2023 https://www.nice.org.uk/guidance/ta934
  3. Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063–73
Persistent identifier live
10.83033/c4312ab4-ff28-453b-b87f-8f1f5ea4f26b

This is a poster presented at a BGS conference. It constitutes research undertaken by the authors  and queries should be addressed to them. The BGS do not endorse or recommend any of the content. BGS do not make any warranties or guarantees in relation to the content.  If you wish to comment on the poster you will need to create a website account, sign in and submit for the authors to respond.